GLAUKOS Corp 4

Director Mark J. Foley received an award of 2,987 Glaukos Corp stock options on May 28, 2026 at a corrected exercise price of $106.52 per share.

On May 28, 2026, director Mark J. Foley received a grant of 2,987 stock options of Glaukos Corp as part of the issuer’s director compensation policy, with an exercise price correctly stated in this amended Form 4 as $106.52 per share (amending a prior misreported price of $53.57). These options, classified as a derivative security (stock option/right to buy), vest in full on May 28, 2027, one year after the grant date, and have an expiration date of May 28, 2036. No shares were purchased or sold for cash in this filing; rather, it reflects a compensatory award that increases Foley’s derivative interest in the company, with 2,987 underlying common shares beneficially owned following the grant, which at the current stock price of about $134.65 implies an underlying equity value of roughly $402,000, though the options are only economically valuable above the $106.52 strike price.

Filing Facts

CIK

1192448

Ticker

GKOS

Form

4

Source Type

fda

Accession

0001529196-26-000006

Alert Tier

5